A mechanism involving potassium channels in the brain that control brain cell activity could provide a new and fundamentally different way of treating depression symptoms in adults with major depressive disorder, according to two complementary papers published recently by researchers at the Icahn School of Medicine at Mount Sinai.
In two new research articles, published in Biological Psychiatry and Molecular Psychiatry, the researchers provide new insights into how a drug called ezogabine may impact the brain to improve depression.